Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Dr. Vinay Prasad, the FDA's new vaccine chief, has been accused of spreading misinformation about Covid vaccines.

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

Dr. Marty Makary, chief of the FDA, has expressed doubts about the agency approving the COVID-19 vaccine for winter, stating ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Vaccine maker Novavax is seeking to convert the 2022 emergency authorization of its Covid-19 vaccine into full approval. Yet ...

The U.S. Food and Drug Administration said on Wednesday it will hold a meeting of experts on May 22 to discuss COVID-19 ...

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

The head of the FDA reiterated that the agency is applying a more skeptical approach to this year’s round of COVID-19 vaccine boosters.

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...